1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment

 
• By Alexandra Shimmings

Shares in UK company Indivior jumped by more than 12% on Aug. 17 on the LSE on the back of top-line Phase III data for its monthly buprenorphine depot for opioid addiction, and confirmation that a Q4 2017 US approval is still within its sights.

Indivior PLC is attempting to follow Braeburn Pharmaceuticals SPRL and Titan Pharmaceuticals Inc. down a new avenue for treating opioid addiction by using long-acting formulations of buprenorphine to improve treatment compliance. Braeburn/Titan's Probuphine implant was approved by the US FDA in May after what was a long and difficult path, and Indivior is looking to gaining approval of its product RBP-6000 on the back of new Phase III data by the end of next year.

Indivior's RBP-6000, which is designed to be used together with counselling and psychosocial support, is a "potentially transformational" treatment for...

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.